ReviewAmerican journal of physiology. Lung cellular and molecular physiology2014
Applying metabolomics to uncover novel biology in ARDS.
Review in American journal of physiology. Lung cellular and molecular physiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 44 citations in OpenAlex.
- The molecular ICU: a primer on omics, informatics and the future of precision critical care.Critical care (London, England) · 2026Review
- The Tip of the Iceberg: Pathway Biology Must Anchor the Next Generation of Critical Care Trials.Critical care explorations · 2026Article
- Differences of respiratory tract flora and metabonomic characteristics of lung lavage fluid in pneumoconiosis model rats.Scientific reports · 2025Article
- A targeted metabolomics approach for sepsis-induced ARDS and its subphenotypes.Critical care (London, England) · 2023Article
- Serum metabolomic signatures of fatty acid oxidation defects differentiate host-response subphenotypes of acute respiratory distress syndrome.Respiratory research · 2023Article
- Identification of a pediatric acute hypoxemic respiratory failure signature in peripheral blood leukocytes at 24 hours post-ICU admission with machine learning.Frontiers in pediatrics · 2023Article
- Metabolomics of Respiratory Diseases.Handbook of experimental pharmacology · 2023Review
- Personalized medicine using omics approaches in acute respiratory distress syndrome to identify biological phenotypes.Respiratory research · 2022Review
- ARDS in the time of corona: context and perspective.American journal of physiology. Lung cellular and molecular physiology · 2022Article
- Pathophysiology of the Acute Respiratory Distress Syndrome: Insights from Clinical Studies.Critical care clinics · 2021Review
- Metabolomics: An emerging potential approach to decipher critical illnesses.Biophysical chemistry · 2020Review
- Therapeutic targeting of metabolic alterations in acute respiratory distress syndrome.European respiratory review : an official journal of the European Respiratory Society · 2020Review
- Systems Biology ARDS Research with a Focus on Metabolomics.Metabolites · 2020Review
- Injury Characteristics and von Willebrand Factor for the Prediction of Acute Respiratory Distress Syndrome in Patients With Burn Injury: Development and Internal Validation.Annals of surgery · 2019Article
- Biomarkers of Acute Lung Injury The Individualized Approach: for Phenotyping, Risk Stratification and Treatment Surveillance.Journal of clinical medicine · 2019Review
- Biomarkers for Acute Respiratory Distress syndrome and prospects for personalised medicine.Journal of inflammation (London, England) · 2019Review
- Evolution of ARDS biomarkers: Will metabolomics be the answer?American journal of physiology. Lung cellular and molecular physiology · 2018Review
- Serum miR-146a and miR-150 as Potential New Biomarkers for Hip Fracture-Induced Acute Lung Injury.Mediators of inflammation · 2018Article
- New Strategies and Challenges in Lung Proteomics and Metabolomics. An Official American Thoracic Society Workshop Report.Annals of the American Thoracic Society · 2017Article
- Airway microbiome research: a modern perspective on surveillance cultures?Annals of translational medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
A better understanding of the pathogenesis and the resolution of the acute respiratory distress syndrome (ARDS) is needed. Although some progress has been made with the use of protein biomarkers and candidate gene studies in understanding the pathobiology of ARDS, we propose that new studies that measure the chemical breakdown products of cellular metabolism (metabolomics) may provide new insights into ARDS, in part because metabolomics targets a later point in the genomics cascade than is possible with studies of DNA, RNA, and protein biomarkers. Technological advances have made large-scale metabolomic profiling increasingly feasible. Metabolomic approaches have already achieved novel insights in nonpulmonary diseases such as diabetes mellitus and malignancy, as well as in sepsis, a major risk factor for developing ARDS. Metabolomic profiling is a promising approach to identify novel pathways in both patients at risk for developing ARDS as well as in the early phase of established ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.